Samuel Mauricio, vice-president for Brazil at Octapharma, one of the largest human protein manufacturers in the world, provides an insightful analysis of the Brazilian plasma market, demonstrating Octapharma’s remarkable willingness to further position itself as the partner of choice for the country’s public healthcare system.
As the head of the Brazilian operations of Octapharma - one of the world's largest producers of plasma products – since 2009, you are in a privileged position to identify the latest and most significant trends shaping the Brazilian ecosystem in this specific segment. Which specificities of the Brazilian market would you highlight to our international readers?
"Our overarching objective is to be recognized as the best company in our area and a frontrunner when it comes to the quality of our processes."
